Simone Scagnoli
@uniroma1.it
Scopus Publications
- Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study
Francesca Ligorio, Leonardo Provenzano, Giuseppe Fotia, Maria Vittori Dieci, Giuseppe Curigliano, Mario Giuliano, Andrea Botticelli, Matteo Lambertini, Gianpiero Rizzo, Rebecca Pedersini, Marianna Sirico, Nicla La Verde, Alessandra Gennari, Alberto Zambelli, Angela Toss, Marta Piras, Monica Giordano, Barbara Tagliaferri, Daniele Generali, Donata Sartori, Giacomo Mazzoli, Flavia Jacobs, Giovanna Armani, Caterina Sposetti, Christian Zurlo, Alice Menichetti, Gaia Griguolo, Valeria Faso, Laura Boldrini, Elisabetta Munzone, Antonio Marra, Edoardo Chiappe, Simone Scagnoli, Simona Pisegna, Camilla Capasso, Carmine De Angelis, Grazia Arpino, Carmen Criscitiello, Valentina Guarneri, Giancarlo Pruneri, Luigi Mariani, Gianpaolo Bianchini, Daniela Miliziano, Matteo De Monte, Chiara Corti, Pier Paolo Berton Giachetti, Ambra Carnevale Schianca, Jalissa Katrini, Maria Silvia Cona, Vincenza Cantile, Angela Grieco, Miriam Pirolo, Maria Zappulo, Maria Anna Rachele De Giglio, Marta Laganà, Deborah Cosentini, Ugo De Giorgi, Andrea Vingiani, Antonino Belfiore, Alice Abate, Valentina Bianchessi, Giuseppe Capri, Giulia Valeria Bianchi, Filippo de Braud, Paolo Baili, Ilaria Cavallo, Cristina Ferraris, Gabriele Martelli, Secondo Folli, Gianfranco Scaperrotta, Catherine Depretto, Angioletta Lasagna, Ornella Ponzoni, Stefano Maccarone, Carla Strina, Silvia Coccato, Rosalinda Coviello, Claudio Vernieri
Breast, 2026
BACKGROUND: Older patients with Hormone Receptor-positive, HER2-negative advanced breast cancer (HR+/HER2- aBC) are often frailer than younger patients. Endocrine therapy (ET) plus CDK4/6 inhibitors (CDK4/6i) is the standard first-line treatment regardless of age; however, CDK4/6i real-world effectiveness in older patients is unknown. PATIENTS AND METHODS: PALMARES-2 (NCT06805812) is a large real-world study investigating first-line ET plus CDK4/6i effectiveness in HR+/HER2- aBC patients. We compared real-world progression-free survival (rwPFS) between older (>75 years) and younger (≤75 years) patients in the whole study cohort, as well as in palbociclib, ribociclib, or abemaciclib sub-cohorts. Cox regression models and inverse probability of treatment weighting (IPTW) were used to adjust for prognostic covariates. RESULTS: Older patients accounted for 302 (15.2%) of the PALMARES-2 study cohort (n = 1982). Compared with younger patients, older patients were less likely to have ECOG PS 0 or bone-only disease, and more likely to receive palbociclib. At multivariable analysis, older patients had better rwPFS when compared to younger patients (aHR 0.77; 95% CI 0.67-0.90, p = 0.001). In younger patients, ribociclib and abemaciclib were more effective than palbociclib, whereas in older patients palbociclib showed similar effectiveness to abemaciclib and superior effectiveness to ribociclib (p for interaction <0.001). Among patients treated with palbociclib, older patients had improved rwPFS compared with younger patients (aHR 0.69; 95% CI 0.57-0.84, p < 0.001). CONCLUSION: First-line ET plus CDK4/6i is highly effective in older patients with HR+/HER2- aBC. Based on effectiveness and clinical manageability, palbociclib represents a particularly suitable option in this population. - Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study
Roberta Scafetta, Raffaella Troiano, Carla Gullotta, Alessandra Guarino, Cristina Fiore, Luisana Sisca, Elena Speziale, Marco Donato, Simone Foderaro, Fabio Venuti, Francesco Antonio Vilardi, Valentina Ricozzi, Michele Iuliani, Sonia Simonetti, Silvia Cavaliere, Alessio Cortellini, Annalisa La Cesa, Andrea Botticelli, Simone Scagnoli, Simona Pisegna, Carmen Criscitiello, Rebecca Pedersini, Caterina Sposetti, Elisa Tiberi, Giuliana D'Auria, Matteo Vergati, Marco Mazzotta, Roberta Caputo, Annarita Verrazzo, Ornella Garrone, Federica Domati, Claudia Piombino, Francesca Sofia Di Lisa, Lorena Filomeno, Teresa Arcuri, Federica Puce, Federica Riva, Michela Palleschi, Marianna Sirico, Marta Piras, Luigia Stefania Stucci, Delia De Lisi, Paolo Orsaria, Antonella Grasso, Edy Ippolito, Sara Ramella, Luca Visani, Lorenzo Livi, Stefania Gori, Luigi Rossi, Icro Meattini, Barbara Tagliaferri, Orazio Caffo, Maria Vittoria Bonomo, Ilaria Portarena, Azzurra Irelli, Elisabetta Cretella, Camillo Porta, Giampaolo Bianchini, Maria Agnese Fabbri, Ugo De Giorgi, Patrizia Vici, Angela Toss, Fiorella Ruatta, Michelino De Laurentiis, Federica Villa, Rossana Berardi, Mauro Minelli, Vittorio Altomare, Claudio Vernieri, Giuseppe Curigliano, Alessandra Chirco, Sara D'Alessandro, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini, Francesco Pantano
European Journal of Cancer, 2026
BACKGROUND: Preclinical evidence suggests that BRCA1/2-mutated tumors may rely on RANKL signaling for survival and proliferation. RANKL inhibition with denosumab could disrupt tumor-bone microenvironment crosstalk and potentially limit metastatic progression. We evaluated the association between denosumab and real-world progression-free survival (rwPFS) in germline BRCA1/2-mutated hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC) with bone metastases. METHODS: We performed a retrospective, multicenter study across 24 Italian hospitals including HR+/HER2- bone mBC patients treated in first- or second-line with a CDK4/6 inhibitor plus endocrine therapy. rwPFS was estimated by Kaplan-Meier and compared with log-rank tests. Center-stratified multivariable Cox models adjusted for clinically relevant covariates were used to assess the association between denosumab exposure and rwPFS. Effect modification by BRCA status was evaluated using a denosumab×BRCA1/2 mutation status. RESULTS: Among 1399 patients, 46 harbored germline BRCA1/2 mutations (13 BRCA1, 33 BRCA2), and 21 of these patients received denosumab. Among patients not receiving denosumab, BRCA1/2-wild-type/unknown patients had better rwPFS than BRCA1/2-mutated patients (median 28 vs 13 months; hazard ratio (HR) 0.48, 95% CI 0.32-0.73; p = 0.001). Among BRCA1/2-wild-type/unknown patients, denosumab use did not affect rwPFS (HR 0.98, 95% CI 0.85-1.12). Conversely, denosumab use was associated with longer rwPFS among patients with BRCA1/2 mutations (median 35 months, 95% CI 24-NR vs 13 months, 95% CI 9-27; HR 0.34, 95% CI 0.16-0.74; p = 0.006), with no significant difference between BRCA1 and BRCA2-mutated subgroups. Multivariable analysis confirmed the rwPFS benefit of denosumab in BRCA1/2-mutated patients (adjusted HR 0.45, 95% CI 0.21-0.99; p = 0.048). CONCLUSION: In this real-world cohort, denosumab use was associated with longer rwPFS in germline BRCA1/2-mutated HR+/HER2- mBC with bone metastases. - Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2− breast cancer patients with bone metastases
Roberta Scafetta, Marco Donato, Carla Gullotta, Alessandra Guarino, Cristina Fiore, Luisana Sisca, Elena Speziale, Raffaella Troiano, Simone Foderaro, Fabio Venuti, Francesco Antonio Vilardi, Valentina Ricozzi, Michele Iuliani, Sonia Simonetti, Silvia Cavaliere, Alessio Cortellini, Annalisa La Cesa, Andrea Botticelli, Simone Scagnoli, Simona Pisegna, Carmen Criscitiello, Alessandra Chirco, Sara D’Alessandro, Rebecca Pedersini, Caterina Sposetti, Elisa Tiberi, Giuliana D’Auria, Matteo Vergati, Marco Mazzotta, Roberta Caputo, Annarita Verrazzo, Maria Grazia Rossino, Federica Domati, Claudia Piombino, Francesca Sofia Di Lisa, Lorena Filomeno, Teresa Arcuri, Federica Puce, Federica Riva, Michela Palleschi, Marianna Sirico, Marta Piras, Luigia Stefania Stucci, Delia De Lisi, Paolo Orsaria, Antonella Grasso, Edy Ippolito, Sara Ramella, Luca Visani, Niccolò Bertini, Ilaria Bonaparte, Stefania Gori, Luigi Rossi, Icro Meattini, Barbara Tagliaferri, Orazio Caffo, Maria Vittoria Bonomo, Ilaria Portarena, Azzurra Irelli, Elisabetta Cretella, Camillo Porta, Giampaolo Bianchini, Maria Agnese Fabbri, Ugo De Giorgi, Patrizia Vici, Angela Toss, Ornella Garrone, Michelino De Laurentiis, Federica Villa, Rossana Berardi, Mauro Minelli, Vittorio Altomare, Claudio Vernieri, Giuseppe Curigliano, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini, Francesco Pantano
Oncologist, 2026
Background The introduction of CDK4/6 inhibitors (CDK4/6i) has improved outcomes in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC), including in patients with bone metastases. Assessing their comparative effectiveness in real-world settings is crucial. Methods This retrospective, multicenter cohort study (January 2019–December 2023; median follow-up 39 months) evaluated the real-world progression-free survival (rwPFS) of abemaciclib, ribociclib, and palbociclib combined with endocrine therapy (ET) in HR+/HER2- mBC patients with bone metastases. Overall survival (OS) was a secondary exploratory endpoint. A total of 1399 patients with ECOG PS 0–1 and at least 12 months of follow-up were included. Analyses used propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) to adjust for confounding. Results Palbociclib showed shorter rwPFS (22 months) compared to abemaciclib (32 months; HR = 1.47, p = 0.001) and ribociclib (35 months; HR = 1.49, p &lt; 0.001). No significant difference was observed between abemaciclib and ribociclib. OS was also lower with palbociclib (47 months) versus abemaciclib (60 months; HR = 1.77, p &lt; 0.001) and ribociclib (64 months; HR = 1.69, p = 0.001). Results were consistent after PSM and IPTW adjustment. CONCLUSION Ribociclib and abemaciclib may provide superior rwPFS and OS compared to palbociclib in HR+/HER2- mBC patients with bone metastases. - Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2
Giacomo Mazzoli, Leonardo Provenzano, Maria Vittoria Dieci, Giuseppe Curigliano, Mario Giuliano, Andrea Botticelli, Matteo Lambertini, Gianpiero Rizzo, Rebecca Pedersini, Marianna Sirico, Nicla La Verde, Alessandra Gennari, Alberto Zambelli, Angela Toss, Marta Piras, Monica Giordano, Barbara Tagliaferri, Daniele Generali, Donata Sartori, Giuseppe Fotia, Matteo De Monte, Francesca Ligorio, Flavia Jacobs, Giovanna Armani, Christian Zurlo, Alice Menichetti, Gaia Griguolo, Valeria Faso, Ambra Carnevale Schianca, Elisabetta Munzone, Antonio Marra, Edoardo Chiappe, Simone Scagnoli, Simona Pisegna, Camilla Capasso, Carmine De Angelis, Grazia Arpino, Carmen Criscitiello, Valentina Guarneri, Giancarlo Pruneri, Luigi Mariani, Claudio Vernieri
Breast, 2026
INTRODUCTION: Invasive lobular breast cancer (ILC) is the second most common breast cancer subtype, with distinctive biological and epidemiologic features. Although phase III trials of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in hormone receptor-positive, HER2-negative advanced breast cancer (HR+/HER2-aBC) included patients with ILC, their real-world effectiveness in this population remains poorly characterized. MATERIAL AND METHODS: In this sub-analysis of the multicenter, real-world PALMARES-2 study (NCT06805812), we assessed the predictive and prognostic value of lobular histology in HR+/HER2-aBC treated with first-line endocrine therapy (ET) plus CDK4/6i. The primary endpoint was real-world progression-free survival (rwPFS). Associations between histology and outcomes were adjusted for 15 covariates using multivariable Cox-regression and inverse probability of treatment weighting. RESULTS: Among 1982 patients, 367 (18.5 %) had ILC and 1481 (74.7 %) non-special type (NST). Median follow-up was 29.8 and 31.2 months, respectively. ILC was associated with shorter rwPFS versus NST (adjusted hazard ratio [aHR]: 1.24, 95 %CI:1.04-1.47, P=0.017). Palbociclib efficacy was not affected by lobular histology (P for interaction = 0.553) while abemaciclib was less effective in ILC (P = 0.009). All three CDK4/6i achieved similar rwPFS in ILC (ribociclib vs palbociclib: aHR: 1.01, 95 %CI: 0.67-1.45, P = 0.949; abemaciclib vs palbociclib: aHR: 1.13, 95 %CI: 0.75-1.71, P = 0.551; abemaciclib vs ribociclib: aHR: 1.15, 95 %CI: 0.73-1.80, P = 0.549). CONCLUSIONS: Tumor histology affects the real-world effectiveness of first line ET plus CDK4/6i. In ILC, all three CDK4/6i performed similarly; therefore, treatment selection should prioritize tolerability, manageability, drug-drug interactions, and patient preferences. - Renal Involvement in Cancer Patients Undergoing Oncology Therapies: Implications for Personalized Treatment Strategies
Silvia Lai, Alessandra Punzo, Adolfo M. Perrotta, Giuseppe Guaglianone, Silverio Rotondi, Paolo Menè, Paolo Izzo, Sara Izzo, Andrea Polistena, Lida Tartaglione, Francesca Tinti, Marta Barattini, Andrea Botticelli, Simone Scagnoli, Daniele Santini, Anna P. Mittherhofer, Giovanni Pintus
Journal of Personalized Medicine, 2026
Introduction: Oncological therapies have significantly improved patient outcomes but are increasingly associated with renal toxicity, which can markedly influence therapeutic decisions. Integrating early identification of kidney injury into clinical workflows is essential for personalized medicine, allowing treatment tailoring based on individual risk profiles. Aim: To evaluate the incidence of acute kidney injury (AKI) and chronic kidney Disease (CKD); assess indices of renal function recovery in patients who developed AKI; and investigate the incidence of renal immune-related adverse events (irAEs) in patients receiving immunotherapy. Materials: Renal function, serum electrolytes, inflammatory markers, blood gas analysis, and urinalysis were evaluated at baseline before oncological therapy (T0), after approximately 2 weeks (T1), and after 3 months (T2). Results: Seventy patients were analyzed (median age 71.5 years). AKI occurred in 43 patients (61.4%) and CKD in 18 (25.7%). Patients receiving immunotherapy displayed significantly higher blood urea nitrogen (p < 0.01) and creatinine (p < 0.01) levels compared to those undergoing traditional therapies (targeted therapy and chemotherapy). Treatment discontinuation was required in 14 (56%) immunotherapy patients versus 7 (19.4%) receiving traditional therapy (anti-VEGF and cisplatin) (p < 0.01). Among 25 immunotherapy-treated patients, 13 (52%) developed immune-related adverse events (irAEs). Patients with irAEs predominantly experienced AKI (92.3%), whereas those without irAEs showed both AKI and CKD (44.4%) (p < 0.01). Treatment discontinuation occurred in 84.6% of patients with irAEs compared to 11.1% without irAEs (p < 0.001). Conclusions: We showed a high incidence of AKI and CKD among cancer patients; in particular, the majority of patients receiving immunotherapy presented irAEs. CKD also occurs in association with comorbidities, such as previous use of NSAIDs, investigations with contrast agents and episodes of AKI on CKD determined by drugs. It seems necessary for there to be multidisciplinary collaboration between oncologists and nephrologists to individualize treatment plans; thus allowing the non-suspension of therapy, which positively influences the prognosis of patients. - Clinical characteristics and drug–drug interactions in human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab deruxtecan: real-world data from the DE-REAL study
Simona Pisegna, Simone Scagnoli, Gabriella Gentile, Antonella Chiavassa, Roberta Caputo, Michelino De Laurentiis, Giuseppe Curigliano, Matteo Lambertini, Francesco Pantano, Armando Orlandi, Antonella Palazzo, Ida Paris, Claudio Vernieri, Beatrice Tedesco, Marianna Giampaglia, Michela Palleschi, Zelmira Ballatore, Daniele Alesini, Giuliana D’Auria, Maria Agnese Fabbri, Luigi Rossi, Giulia Fiscon, Paolo Marchetti, Alessandra Fabi, Andrea Botticelli
Oncologist, 2026
Background Trastuzumab deruxtecan (T-DXd) reshaped clinical practice in human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC). The impact of clinical characteristics and drug–drug interactions (DDIs) on outcomes in patients receiving T-DXd is still under investigation. Methods We retrospectively analyzed data of patients from the Italian DE-REAL study. Clinical features including age, body mass index (BMI), toxicity and DDIs were assessed and correlated with clinical outcomes. The Drug-PIN software was used to evaluate DDIs. Results Among 143 patients, age did not significantly affect progression-free survival (PFS) but influenced overall survival (OS), with younger patients (&lt;65 years) showing better outcomes (median overall survival [mOS]: 12 vs. 10 months, P = 0.02). Patients with BMI &gt;25 demonstrated significantly longer PFS (11 vs. 9 months, P = 0.04), which was confirmed as independent predictor of better PFS at multivariate analysis (P ≤0.05), but experienced higher toxicity rates, particularly nausea (P = 0.019). Drug-PIN classification showed no impact on survival outcomes, although patients with high-risk DDIs experienced more nausea and asthenia compared to those with low-risk interactions (P = 0.0018 and P = 0.003, respectively). Conclusion T-DXd efficacy appears consistent across different age groups, although elderly patients showed reduced OS. Higher BMI was associated with improved PFS but increased toxicity. While DDIs did not affect survival outcomes, they influenced specific adverse events. Our results reinforce the efficacy and favorable safety profile of T-DXd in a broad real-world population, including patients with polypharmacy or comorbidities, while highlighting that personalized monitoring and supportive care strategies may be particularly beneficial for elderly patients and those with higher BMI. - The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
Andrea Botticelli, Chiara Cremolini, Simone Scagnoli, Mauro Biffoni, Sara Lonardi, Lorenzo Fornaro, Valentina Guarneri, Ugo De Giorgi, Paolo Antonio Ascierto, Giovanni Blandino, Giulia D’Amati, Massimo Aglietta, Pierfranco Conte, Edoardo Crimini, Maurizio Ceracchi, Simona Pisegna, Sofia Verkhovskaia, Roberto Bordonaro, Sergio Bracarda, Giovanni Butturini, Lucia Del Mastro, Andrea DeCensi, Agnese Fabbri, Elisabetta Fenocchio, Stefania Gori, Giulio Metro, Annamaria Pessino, Daniele Pozzessere, Fabio Puglisi, Stefano Tamberi, Alberto Zambelli, Donatella Marino, Ettore Capoluongo, Federico Cappuzzo, Bruna Cerbelli, Giuseppe Giannini, Umberto Malapelle, Federica Mazzuca, Marianna Nuti, Giancarlo Pruneri, Maurizio Simmaco, Lidia Strigari, Giuseppe Tonini, Nello Martini, Giuseppe Curigliano, Paolo Marchetti
Clinical Cancer Research, 2026
Purpose: This analysis evaluated the influence of tissue and liquid biopsy concordance on outcomes in patients enrolled in the ROME trial. Patients and Methods: The ROME trial, a phase II multicenter study, enrolled 1,794 patients with advanced solid tumors. Next-generation sequencing was performed on tissue and liquid biopsies using FoundationOne CDx and FoundationOne Liquid CDx. A centralized molecular tumor board reviewed results to identify actionable alterations, with 400 patients randomly assigned to tailored therapy (TT) or standard-of-care groups. TT improved objective response rate and progression-free survival (PFS) in the intention-to-treat population. Concordance was defined as the detection of the same druggable alteration in both biopsy types; discordance indicated detection in only one. Results: Concordance was present in 49% of cases, with alterations detected exclusively in tissue (35%) or liquid (16%) biopsies. Patients in the concordant group receiving TT experienced improved survival outcomes. The median overall survival was 11.05 versus 7.70 months in the standard-of-care group [HR = 0.74; 95% confidence interval, 0.51–1.07], and the median PFS was 4.93 versus 2.80 months (HR = 0.55; 95% confidence interval, 0.40–0.76), respectively. In contrast, the survival benefit of TT was less pronounced or absent in patients with discordant results. Overall survival was higher in the T + L group (11.05 months), followed by tissue-only (9.93 months) and liquid-only (4.05 months) groups. PFS followed a similar pattern, with the longest PFS in the T + L group (4.93 months) versus 3.06 months in tissue-only and 2.07 months in liquid-only groups. Conclusions: The study highlights the potential value of integrating both biopsy modalities in selected clinical contexts. See related commentary by Saldanha and Siu, p. 7 - Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment
Beatrice Taurelli Salimbeni, Fabiola Giudici, Carlo Pescia, Pier Paolo Maria Berton Giachetti, Roberta Scafetta, Paola Zagami, Antonio Marra, Dario Trapani, Angela Esposito, Simone Scagnoli, Bruna Cerbelli, Andrea Botticelli, Elisabetta Munzone, Nicola Fusco, Carmen Criscitiello, Giuseppe Curigliano
Npj Breast Cancer, 2025
Breast cancer (BC) is a leading cause of death among women, with approximately 30% HER2-positive (HER2+). Although HER2-targeted therapies have improved outcomes for patients with HER2+ metastatic breast cancer (mBC), clinical challenges and prognostic variability remain. Tumor-infiltrating lymphocytes (TILs) have emerged as prognostic and predictive biomarkers in various tumors, including BC, but their role in HER2+ mBC is poorly understood. This multicentric retrospective cohort study evaluated the prognostic significance of TILs in 110 patients with HER2+ mBC treated with pertuzumab, trastuzumab, and taxane-based chemotherapy at two Italian institutes from June 2013 to May 2024. TILs were assessed on metastatic or primary tumor samples. High TILs levels (>5%) were independently associated with longer PFS and OS. TILs levels were higher in primary tumours than in metastases (p = 0.009), with significant variation by metastatic site. These findings underscore the potential of TILs as prognostic biomarkers in HER2+ mBC, necessitating further prospective studies. - Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan
Alessandra Fabi, Alessandro Rossi, Roberta Caputo, Simona Pisegna, Simone Scagnoli, Francesco Pantano, Giuliana D’Auria, Palma Fedele, Agnese Fabbri, Claudio Vernieri, Michela Palleschi, Luisa Carbognin, Gianluigi Ferretti, Elena Di Monte, Ida Paris, Francesco Pavese, Ornella Garrone, Antonio Franco, Michelino De Laurentiis, Gianluca Franceschini, Giovanni Scambia, Diana Giannarelli, Riccardo Masetti, Andrea Botticelli
Npj Precision Oncology, 2025
Tumor dissemination to the central nervous system (CNS) is almost a rule in the treatment journey of advanced HER2+ breast cancer (BC). Recent results demonstrated high intracranial efficacy with Trastuzumab Deruxtecan (T-DXd). However, a real-world evidence is lacking in literature. We conducted a multicenter, observational, retrospective real-world analysis on 39 cases collected at 12 Italian Oncological Units. Patients with brain metastases (BMs) from HER2 + BC treated with T-DXd in various treatment lines were enrolled. Primary endpoint was the intracranial overall response rate (iORR). Secondary endpoints were intra- and global progression free survival (iPFS - gPFS); other secondary objectives were the intracranial disease control rate (iDCR), duration of response (iDoR), clinical benefit rate at 6 and 12 months (iCBr), overall survival, and safety. iORR was 59%, iPFS was 15.6 months, gPFS was 11.8 months. iDCR was 94.9%, iDoR was 11.9 months, and iCBr at 6 and 12 months were 69.2% and 59%, respectively. OS was not reached, with an overall rate of 77.9% of patients alive at 12 months. This study confirmed the high intracranial efficacy and manageable safety profile of T-DXd in this first-ever real world analysis. - ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy
Konstantinos Venetis, Giulia Cursano, Roberta Scafetta, Pier Paolo Maria Berton Giachetti, Alberto Concardi, Elisa De Camilli, Marianna D’Ercole, Eltjona Mane, Chiara Frascarelli, Antonio Marra, Sara Gandini, Francesco Pepe, Simone Scagnoli, Silvia Maria Rossi, Raffaella Troiano, Elena Speziale, Carmine De Angelis, Giancarlo Troncone, Umberto Malapelle, Giuseppe Perrone, Andrea Botticelli, Giuseppe Viale, Giuseppe Curigliano, Elena Guerini Rocco, Carmen Criscitiello, Nicola Fusco
Breast Cancer Research, 2025
Mutations in ESR1 play a critical role in resistance to endocrine therapy (ET) in hormone receptor-positive (HR +)/HER2- metastatic breast cancer (MBC). Testing for ESR1 mutations is essential for guiding treatment with novel oral selective estrogen receptor degraders (SERDs) like elacestrant or camizestrant. While most studies have utilized liquid biopsy (LB) for mutation detection, the role of formalin-fixed paraffin-embedded (FFPE) tissue biopsy in this context remains unclear. In this study, we analyzed a cohort of HR + /HER2- MBC patients who experienced resistance to ET and CDK4/6 inhibitors. Next-generation sequencing (NGS) was performed on FFPE biopsy samples obtained from metastatic sites at the time of disease progression. ESR1 mutations were detected in 24 out of 38 patients (63.2%), with p.D538G identified in 10 patients (45.5%) and p.Y537S in 6 patients (27.2%) as the most frequent alterations. One patient exhibited dual ESR1 mutations, and a recurrent ESR1-CCDC170 gene fusion was identified, underscoring the diversity and potential interplay of genetic alterations driving resistance in HR + /HER2- MBC. Notably, lung metastases were significantly more common in ESR1 mutant cases (8/24, 33.3%) compared to wild-type cases (1/14, 7.1%), while liver metastases showed no difference between mutant (12/24, 50.0%) and wild-type groups (7/14, 50.0%). Co-mutations in actionable pathways, particularly PIK3CA, were observed in n = 10 ESR1 mutant tumors (41.6%), highlighting their contribution to resistance mechanisms and posing significant challenges for treatment selection, as these alterations may necessitate combination therapies to effectively target multiple resistance pathways. This study presents new insights into the prevalence and clinical significance of ESR1 mutations in HR + /HER2- MBC, highlighting the potential utility of FFPE biopsy samples as a viable alternative or complementary approach to LB for mutation detection, particularly in resource-limited settings where access to ctDNA analysis may be constrained. - Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial
Paolo Marchetti, Giuseppe Curigliano, Mauro Biffoni, Sara Lonardi, Simone Scagnoli, Lorenzo Fornaro, Valentina Guarneri, Ugo De Giorgi, Paolo Antonio Ascierto, Giovanni Blandino, Giulia D’Amati, Massimo Aglietta, Chiara Cremolini, Pierfranco Conte, Edoardo Crimini, Maurizio Ceracchi, Simona Pisegna, Sofia Verkhovskaia, Roberto Bordonaro, Sergio Bracarda, Giovanni Butturini, Lucia Del Mastro, Andrea DeCensi, Agnese Fabbri, Elisabetta Fenocchio, Stefania Gori, Giulio Metro, Annamaria Pessino, Daniele Pozzessere, Fabio Puglisi, Stefano Tamberi, Alberto Zambelli, Donatella Marino, Ettore Capoluongo, Federico Cappuzzo, Bruna Cerbelli, Giuseppe Giannini, Umberto Malapelle, Federica Mazzuca, Marianna Nuti, Giancarlo Pruneri, Maurizio Simmaco, Lidia Strigari, Giuseppe Tonini, Nello Martini, Andrea Botticelli, , Antonella Savarese, Vincenzo Adamo, Davide Quaresmini, Pierosandro Tagliaferri, Paola Damiano, Benedetta Urbini, Carmelo Bengala, Elena Zaffignani, Carmine Pinto, Alicia Tosoni, Lucio Buffoni, Evaristo Maiello, Claudia Mucciarini, Antonio Russo, Rossana Berardi, Giuseppe Lombardi, Alessandra Piancastelli, Gianluca Masi, Laura Bonanno, Vito Vanella, Francesca Mannozzi
Nature Medicine, 2025 - Impact of Body Composition Changes on Treatment-Related Toxicities and Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Patients Receiving Trastuzumab Deruxtecan
Alessio Molfino, Giovanni Imbimbo, Simona Pisegna, Simone Scagnoli, Claudia Alabiso, Massimiliano Ardovino, Carmen Gallicchio, Veronica Rizzo, Andrea Botticelli
Cancers, 2025 - Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors
Roberta Scafetta, Marco Donato, Carla Gullotta, Alessandra Guarino, Cristina Fiore, Luisana Sisca, Elena Speziale, Raffaella Troiano, Simone Foderaro, Valentina Ricozzi, Michele Iuliani, Sonia Simonetti, Silvia Cavaliere, Alessio Cortellini, Andrea Botticelli, Simone Scagnoli, Simona Pisegna, Carmen Criscitiello, Rebecca Pedersini, Caterina Sposetti, Elisa Tiberi, Giuliana D'Auria, Matteo Vergati, Marco Mazzotta, Roberta Caputo, Annarita Verrazzo, Maria Grazia Rossino, Federica Domati, Claudia Piombino, Francesca Sofia Di Lisa, Lorena Filomeno, Teresa Arcuri, Federica Puce, Federica Riva, Michela Palleschi, Marianna Sirico, Marta Piras, Luigia Stefania Stucci, Delia De Lisi, Paolo Orsaria, Edy Ippolito, Sara Ramella, Luca Visani, Niccolò Bertini, Ilaria Bonaparte, Stefania Gori, Luigi Rossi, Icro Meattini, Barbara Tagliaferri, Orazio Caffo, Ilaria Portarena, Azzurra Irelli, Elisabetta Cretella, Camillo Porta, Giampaolo Bianchini, Agnese Fabbri, Ugo De Giorgi, Patrizia Vici, Angela Toss, Ornella Garrone, Michelino De Laurentiis, Federica Villa, Rossana Berardi, Mauro Minelli, Claudio Vernieri, Giuseppe Curigliano, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini, Francesco Pantano
Breast, 2025 - Impact of Drug–Drug Interactions on Clinical Outcomes in Metastatic Melanoma Patients Treated With Combined BRAF/MEK Inhibitors: A Real-World Study
Silvia Mezi, Andrea Botticelli, Giulia Pomati, Simone Scagnoli, Giulia Fiscon, Federica de Galitiis, Francesca Romana di Pietro, Sofia Verkhovskaia, Sasan Amirhassankhani, Giovanna Gentile, Maurizio Simmaco, Bjoern Gohlke, Robert Preissner, Daniele Santini, Paolo Marchetti
Pigment Cell and Melanoma Research, 2025 - Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study
L. Provenzano, M.V. Dieci, G. Curigliano, M. Giuliano, A. Botticelli, M. Lambertini, G. Rizzo, R. Pedersini, M. Sirico, N. La Verde, A. Gennari, A. Zambelli, A. Toss, M. Piras, M. Giordano, B. Tagliaferri, D. Generali, D. Sartori, D. Miliziano, A. Menichetti, F. Ligorio, C. Zurlo, G. Griguolo, P.P. Berton Giachetti, V. Faso, C. Corti, E. Chiappe, S. Scagnoli, S. Pisegna, C. Capasso, C. De Angelis, G. Arpino, C. Criscitiello, V. Guarneri, G. Pruneri, L. Mariani, C. Vernieri, G. Bianchini, E. Munzone, A. Marra, L. Boldrini, A. Carnevale Schianca, J. Katrini, M.S. Cona, V. Cantile, A. Grieco, M. Pirolo, M. Zappulo, M.A.R. De Giglio, M. Laganà, D. Cosentini, U. De Giorgi, A. Vingiani, A. Belfiore, G. Fotia, G. Mazzoli, C. Sposetti, A. Abate, V. Bianchessi, G. Capri, G.V. Bianchi, F. de Braud, P. Baili, G. Scaperrotta, C. Depretto, A. Lasagna, F. Jacobs, O. Ponzoni, S. Maccarone, C. Strina, S. Coccato, R. Coviello
Annals of Oncology, 2025 - Association between body composition parameters and treatment-related toxicities in patients with metastatic breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors
Giovanni Imbimbo, Marica Pellegrini, Simone Scagnoli, Simona Pisegna, Veronica Rizzo, Carmen Gallicchio, Andrea Botticelli, Alessio Molfino
Clinical Nutrition, 2025 - Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2–Negative Metastatic Breast Cancer
Pier Paolo Maria Berton Giachetti, Stefania Morganti, Sara Gandini, Fabiola Giudici, Antonio Marra, Eleonora Nicolò, Emma Zattarin, Chiara Corti, Laura Boldrini, Annarita Verrazzo, Caterina Sposetti, Maria Grazia Razeti, Ambra Carnevale Schianca, Roberta Scafetta, Beatrice Taurelli Salimbeni, Angela Esposito, Paola Zagami, Dario Trapani, Bianca Malagutti, Roberta Caputo, Claudio Vernieri, Elisabetta Munzone, Simone Scagnoli, Andrea Botticelli, Matteo Lambertini, Mario Giuliano, Michelino De Laurentiis, Giulia Viale, Giampaolo Bianchini, Giuseppe Curigliano, Carmine De Angelis, Carmen Criscitiello
JAMA Network Open, 2025 - Adherence to Aromatase Inhibitor Therapy in Breast Cancer: Insights From a Multicenter Italian Study
Maria Agnese Fabbri, Alberto Fulvi, Matteo Vergati, Giuliana D’Auria, Patrizia Vici, Lorena Filomeno, Teresa Arcuri, Antonella Palazzo, Fabrizio Nelli, Cristina Fiore, Ilaria Portarena, Pina Tiziana Falbo, Rosalinda Rossi, Daniele Alesini, Valentina Sini, Roberta Pace, Patrizia Frittelli, Domenico Cristiano Corsi, Lucia Palombi, Simona Pisegna, Andrea Botticelli, Simone Scagnoli, Giorgio Pistillucci, Erica Giordani, Annalisa La Cesa
Breast Journal, 2025 - Correction to: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study (npj Breast Cancer, (2024), 10, 1, (58), 10.1038/s41523-024-00657-z)
Simone Scagnoli, Simona Pisegna, Angela Toss, Roberta Caputo, Michelino De Laurentiis, Michela Palleschi, Ugo de Giorgi, Enrico Cortesi, Agnese Fabbri, Alessandra Fabi, Ida Paris, Armando Orlandi, Giuseppe Curigliano, Carmen Criscitiello, Ornella Garrone, Gianluca Tomasello, Giuliana D’Auria, Patrizia Vici, Enrico Ricevuto, Federica Domati, Claudia Piombino, Sara Parola, Roberta Scafetta, Alessio Cirillo, Beatrice Taurelli Salimbeni, Francesca Sofia Di Lisa, Lidia Strigari, Robert Preissner, Maurizio Simmaco, Daniele Santini, Paolo Marchetti, Andrea Botticelli
Npj Breast Cancer, 2024 - Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study
Simone Scagnoli, Simona Pisegna, Angela Toss, Roberta Caputo, Michelino De Laurentiis, Michela Palleschi, Ugo de Giorgi, Enrico Cortesi, Agnese Fabbri, Alessandra Fabi, Ida Paris, Armando Orlandi, Giuseppe Curigliano, Carmen Criscitiello, Ornella Garrone, Gianluca Tomasello, Giuliana D’Auria, Patrizia Vici, Enrico Ricevuto, Federica Domati, Claudia Piombino, Sara Parola, Roberta Scafetta, Alessio Cirillo, Beatrice Taurelli Salimbeni, Francesca Sofia Di Lisa, Lidia Strigari, Robert Preissner, Maurizio Simmaco, Daniele Santini, Paolo Marchetti, Andrea Botticelli
Npj Breast Cancer, 2024 - Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments
Fiorenza Santamaria, Michela Roberto, Dorelsa Buccilli, Mattia Alberto Di Civita, Paola Giancontieri, Giulia Maltese, Francesco Nicolella, Andrea Torchia, Simone Scagnoli, Simona Pisegna, Giacomo Barchiesi, Iolanda Speranza, Andrea Botticelli, Daniele Santini
Critical Reviews in Oncology Hematology, 2024 - Assessing risks and knowledge gaps on the impact of systemic therapies in early breast cancer on female fertility: A systematic review of the literature
Gabriella Gentile, Simone Scagnoli, Luca Arecco, Daniele Santini, Andrea Botticelli, Matteo Lambertini
Cancer Treatment Reviews, 2024 - Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study
Andrea Botticelli, Roberta Caputo, Simone Scagnoli, Simona Pisegna, Michelino De Laurentiis, Giuseppe Curigliano, Matteo Lambertini, Francesco Pantano, Antonella Palazzo, Ida Paris, Claudio Vernieri, Beatrice Tedesco, Marianna Giampaglia, Michela Palleschi, Zelmira Ballatore, Daniele Alesini, Giuliana D’Auria, Agnese Fabbri, Luigi Rossi, Annarita Verrazzo, Roberta Scafetta, Daniele Marinelli, Caterina Sposetti, Vittoria Barberi, Lidia Strigari, Paolo Marchetti, Daniele Santini, Alessandra Fabi
Oncologist, 2024 - Network approach in liquidomics landscape
Daniele Santini, Andrea Botticelli, Antonio Galvano, Michele Iuliani, Lorena Incorvaia, Valerio Gristina, Chiara Taffon, Simone Foderaro, Elisa Paccagnella, Sonia Simonetti, Federico Fazio, Simone Scagnoli, Giulia Pomati, Francesco Pantano, Giuseppe Perrone, Elena De Falco, Antonio Russo, Gian Paolo Spinelli
Journal of Experimental and Clinical Cancer Research, 2023 - The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma
Silvia Mezi, Andrea Botticelli, Simone Scagnoli, Giulia Pomati, Giulia Fiscon, Federica De Galitiis, Francesca Romana Di Pietro, Sofia Verkhovskaia, Sasan Amirhassankhani, Simona Pisegna, Giovanna Gentile, Maurizio Simmaco, Bjoern Gohlke, Robert Preissner, Paolo Marchetti
Cancers, 2023 - Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach
Andrea Botticelli, Alessio Cirillo, Giulia Pomati, Enrico Cortesi, Ernesto Rossi, Giovanni Schinzari, Giampaolo Tortora, Silverio Tomao, Giulia Fiscon, Lorenzo Farina, Simone Scagnoli, Simona Pisegna, Fabio Ciurluini, Antonella Chiavassa, Sasan Amirhassankhani, Fulvia Ceccarelli, Fabrizio Conti, Alessandra Di Filippo, Ilaria Grazia Zizzari, Chiara Napoletano, Aurelia Rughetti, Marianna Nuti, Silvia Mezi, Paolo Marchetti
Cancer Immunology Immunotherapy, 2023 - Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study
Luca Cantini, Francesco Paoloni, Federica Pecci, Francesco Spagnolo, Carlo Genova, Enrica Teresa Tanda, Sophie Aerts, Sara Elena Rebuzzi, Giuseppe Fornarini, Federica Zoratto, Sara Fancelli, Alessio Lupi, Carminia Maria Della Corte, Alessandro Parisi, Chiara Bennati, Cinzia Ortega, Francesco Atzori, Pier Luigi Piovano, Corrado Orciuolo, Michele De Tursi, Michele Ghidini, Andrea Botticelli, Simone Scagnoli, Lorenzo Belluomini, Rita Leporati, Antonello Veccia, Anna Maria Di Giacomo, Lucia Festino, Diego Cortinovis, Mirko Acquati, Marco Filetti, Raffaele Giusti, Marco Tucci, Maria Chiara Sergi, Mattia Garutti, Fabio Puglisi, Sara Manglaviti, Fabrizio Citarella, Matteo Santoni, Erika Rijavec, Giuseppe Lo Russo, Daniele Santini, Alfredo Addeo, Lorenzo Antonuzzo, Alice Indini, Marco Bruno Luigi Rocchi, Alessio Cortellini, Francesco Grossi, Paolo Antonio Ascierto, Joachim G J V Aerts, Rossana Berardi
Journal of the National Cancer Institute, 2023 - Circulating CD137+ T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients
Alessio Cirillo, Ilaria Grazia Zizzari, Andrea Botticelli, Lidia Strigari, Hassan Rahimi, Simone Scagnoli, Fabio Scirocchi, Angelina Pernazza, Angelica Pace, Bruna Cerbelli, Giulia d’Amati, Paolo Marchetti, Marianna Nuti, Aurelia Rughetti, Chiara Napoletano
International Journal of Molecular Sciences, 2023 - Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study
Fabrizio Nelli, Agnese Fabbri, Andrea Botticelli, Diana Giannarelli, Eleonora Marrucci, Cristina Fiore, Antonella Virtuoso, Julio Rodrigo Giron Berrios, Simone Scagnoli, Simona Pisegna, Alessio Cirillo, Valentina Panichi, Annalisa Massari, Maria Assunta Silvestri, Enzo Maria Ruggeri
Frontiers in Oncology, 2023 - Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study
Agnese Fabbri, Fabrizio Nelli, Andrea Botticelli, Diana Giannarelli, Eleonora Marrucci, Cristina Fiore, Antonella Virtuoso, Simone Scagnoli, Simona Pisegna, Daniele Alesini, Valentina Sini, Armando Orlandi, Alessandra Fabi, Federico Piacentini, Luca Moscetti, Giuliana D’Auria, Teresa Gamucci, Marco Mazzotta, Laura Pizzuti, Patrizia Vici, Elisabetta Cretella, Paola Scavina, Annalisa La Cesa, Mara Persano, Francesco Atzori, Enzo Maria Ruggeri
Frontiers in Oncology, 2023 - Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study
Francesca Sofia Di Lisa, Eriseld Krasniqi, Laura Pizzuti, Maddalena Barba, Katia Cannita, Ugo De Giorgi, Fulvio Borella, Jennifer Foglietta, Anna Cariello, Antonella Ferro, Elisa Picardo, Marco Mitidieri, Valentina Sini, Simonetta Stani, Giuseppe Tonini, Daniele Santini, Nicla La Verde, Anna Rita Gambaro, Antonino Grassadonia, Nicola Tinari, Ornella Garrone, Giuseppina Sarobba, Lorenzo Livi, Icro Meattini, Giuliana D’Auria, Matteo Vergati, Teresa Gamucci, Mirco Pistelli, Rossana Berardi, Emanuela Risi, Francesco Giotta, Vito Lorusso, Lucia Rinaldi, Salvatore Artale, Marina Elena Cazzaniga, Fable Zustovich, Federico Cappuzzo, Lorenza Landi, Rosalba Torrisi, Simone Scagnoli, Andrea Botticelli, Andrea Michelotti, Beatrice Fratini, Rosa Saltarelli, Ida Paris, Margherita Muratore, Alessandra Cassano, Lorenzo Gianni, Valeria Gaspari, Enzo Maria Veltri, Federica Zoratto, Elena Fiorio, Maria Agnese Fabbri, Marco Mazzotta, Enzo Maria Ruggeri, Rebecca Pedersini, Maria Rosaria Valerio, Lorena Filomeno, Mauro Minelli, Paola Scavina, Mimma Raffaele, Antonio Astone, Roy De Vita, Marcello Pozzi, Ferdinando Riccardi, Filippo Greco, Luca Moscetti, Monica Giordano, Marcello Maugeri-Saccà, Alessandro Zennaro, Claudio Botti, Fabio Pelle, Sonia Cappelli, Flavia Cavicchi, Enrico Vizza, Giuseppe Sanguineti, Federica Tomao, Enrico Cortesi, Paolo Marchetti, Silverio Tomao, Iolanda Speranza, Isabella Sperduti, Gennaro Ciliberto, Patrizia Vici
Frontiers in Oncology, 2023 - The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy
Andrea Botticelli, Giulia Pomati, Alessio Cirillo, Simone Scagnoli, Simona Pisegna, Antonella Chiavassa, Ernesto Rossi, Giovanni Schinzari, Giampaolo Tortora, Francesca Romana Di Pietro, Bruna Cerbelli, Alessandra Di Filippo, Sasan Amirhassankhani, Alessandro Scala, Ilaria Grazia Zizzari, Enrico Cortesi, Silverio Tomao, Marianna Nuti, Silvia Mezi, Paolo Marchetti
Frontiers in Immunology, 2022 - Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: Relief from immunosuppression is associated with clinical response
Fabio Scirocchi, Simone Scagnoli, Andrea Botticelli, Alessandra Di Filippo, Chiara Napoletano, Ilaria Grazia Zizzari, Lidia Strigari, Silverio Tomao, Enrico Cortesi, Aurelia Rughetti, Paolo Marchetti, Marianna Nuti
Ebiomedicine, 2022 - The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature
Andrea Botticelli, Agnese Fabbri, Michela Roberto, Daniele Alesini, Alessio Cirillo, Giuliana D’Auria, Eriseld Krasniqi, Eleonora Marrucci, Margherita Muratore, Francesco Pantano, Laura Pizzuti, Ilaria Portarena, Rosalina Rossi, Simone Scagnoli, Paolo Marchetti
Frontiers in Oncology, 2022 - The role of opioids in cancer response to immunotherapy
Andrea Botticelli, Alessio Cirillo, Giulia Pomati, Bruna Cerbelli, Simone Scagnoli, Michela Roberto, Alain Gelibter, Giulia Mammone, Maria Letizia Calandrella, Edoardo Cerbelli, Francesca Romana Di Pietro, Federica De Galitiis, Gaetano Lanzetta, Enrico Cortesi, Silvia Mezi, Paolo Marchetti
Journal of Translational Medicine, 2021 - PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
Laura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, Maddalena Barba, Teresa Gamucci, Maria Mauri, Enzo Maria Veltri, Icro Meattini, Rossana Berardi, Francesca Sofia Di Lisa, Clara Natoli, Mirco Pistelli, Laura Iezzi, Emanuela Risi, Nicola D’Ostilio, Silverio Tomao, Corrado Ficorella, Katia Cannita, Ferdinando Riccardi, Alessandra Cassano, Emilio Bria, Maria Agnese Fabbri, Marco Mazzotta, Giacomo Barchiesi, Andrea Botticelli, Giuliana D’Auria, Anna Ceribelli, Andrea Michelotti, Antonio Russo, Beatrice Taurelli Salimbeni, Giuseppina Sarobba, Francesco Giotta, Ida Paris, Rosa Saltarelli, Daniele Marinelli, Domenico Corsi, Elisabetta Maria Capomolla, Valentina Sini, Luca Moscetti, Lucia Mentuccia, Giuseppe Tonini, Mimma Raffaele, Luca Marchetti, Mauro Minelli, Enzo Maria Ruggeri, Paola Scavina, Olivia Bacciu, Nello Salesi, Lorenzo Livi, Nicola Tinari, Antonino Grassadonia, Angelo Fedele Scinto, Rosalinda Rossi, Maria Rosaria Valerio, Elisabetta Landucci, Simonetta Stani, Beatrice Fratini, Marcello Maugeri-Saccà, Michele De Tursi, Angela Maione, Daniele Santini, Armando Orlandi, Vito Lorusso, Enrico Cortesi, Giuseppe Sanguineti, Paola Pinnarò, Federico Cappuzzo, Lorenza Landi, Claudio Botti, Federica Tomao, Sonia Cappelli, Giulia Bon, Fabio Pelle, Flavia Cavicchi, Elena Fiorio, Jennifer Foglietta, Simone Scagnoli, Paolo Marchetti, Gennaro Ciliberto, Patrizia Vici
Therapeutic Advances in Medical Oncology, 2021 - Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
Andrea Botticelli, Alessio Cirillo, Lidia Strigari, Filippo Valentini, Bruna Cerbelli, Simone Scagnoli, Edoardo Cerbelli, Ilaria Grazia Zizzari, Carlo Della Rocca, Giulia D’Amati, Antonella Polimeni, Marianna Nuti, Marco Carlo Merlano, Silvia Mezi, Paolo Marchetti
Frontiers in Immunology, 2021 - The role of soluble lag3 and soluble immune checkpoints profile in advanced head and neck cancer: A pilot study
Andrea Botticelli, Ilaria Grazia Zizzari, Simone Scagnoli, Giulia Pomati, Lidia Strigari, Alessio Cirillo, Bruna Cerbelli, Alessandra Di Filippo, Chiara Napoletano, Fabio Scirocchi, Aurelia Rughetti, Marianna Nuti, Silvia Mezi, Paolo Marchetti
Journal of Personalized Medicine, 2021 - Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET)
Claudio Vernieri, Federico Nichetti, Luca Lalli, Luca Moscetti, Carlo Alberto Giorgi, Gaia Griguolo, Antonio Marra, Giovanni Randon, Carmen G. Rea, Francesca Ligorio, Simone Scagnoli, Claudia De Angelis, Chiara Molinelli, Agnese Fabbri, Emanuela Ferraro, Dario Trapani, Andrea Milani, Elisa Agostinetto, Ottavia Bernocchi, Giovanna Catania, Amelia Vantaggiato, Michela Palleschi, Anna Moretti, Debora Basile, Marika Cinausero, Arta Ajazi, Lorenzo Castagnoli, Salvatore Lo Vullo, Lorenzo Gerratana, Fabio Puglisi, Nicla La Verde, Grazia Arpino, Andrea Rocca, Mariangela Ciccarese, Rebecca Pedersini, Alessandra Fabi, Daniele Generali, Agnese Losurdo, Filippo Montemurro, Giuseppe Curigliano, Lucia Del Mastro, Andrea Michelotti, Enrico Cortesi, Valentina Guarneri, Giancarlo Pruneri, Luigi Mariani, Filippo de Braud
Clinical Cancer Research, 2021 - Second medical opinion in oncological setting
Marco Maruzzo, Nicla La Verde, Antonio Russo, Paolo Marchetti, Simone Scagnoli, Ornella Gonzato, Massimo Di Maio, Vittorina Zagonel, Antonio Galvano, Gaetano Lanzetta, Francesco Perrone, Giordano Beretta, Roberto Bordonaro, Alessandro Comandone, Saverio Cinieri, Fabrizio Nicolis, Stefania Gori
Critical Reviews in Oncology Hematology, 2021 - Standard of care and promising new agents for the treatment of mesenchymal triple-negative breast cancer
Silvia Mezi, Andrea Botticelli, Giulia Pomati, Bruna Cerbelli, Simone Scagnoli, Sasan Amirhassankhani, Giulia d’Amati, Paolo Marchetti
Cancers, 2021 - Cdk4/6 inhibitor treatments in patients with hormone receptor positive, her2 negative advanced breast cancer: Potential molecular mechanisms, clinical implications and future perspectives
Michela Roberto, Antonio Astone, Andrea Botticelli, Luisa Carbognin, Alessandra Cassano, Giuliana D’Auria, Agnese Fabbri, Alessandra Fabi, Teresa Gamucci, Eriseld Krasniqi, Mauro Minelli, Armando Orlandi, Francesco Pantano, Ida Paris, Laura Pizzuti, Ilaria Portarena, Nello Salesi, Simone Scagnoli, Paola Scavina, Giuseppe Tonini, Patrizia Vici, Paolo Marchetti
Cancers, 2021 - 5-Fluorouracil degradation rate as a predictive biomarker of toxicity in breast cancer patients treated with capecitabine
Andrea Botticelli, Simone Scagnoli, Michela Roberto, Luana Lionetto, Bruna Cerbelli, Maurizio Simmaco, Paolo Marchetti
Journal of Oncology Pharmacy Practice, 2020 - Soluble immune checkpoints, gut metabolites and performance status as parameters of response to nivolumab treatment in NSCLC patients
Ilaria Zizzari, Alessandra Di Filippo, Fabio Scirocchi, Francesca Di Pietro, Hassan Rahimi, Alessio Ugolini, Simone Scagnoli, Pamela Vernocchi, Federica Del Chierico, Lorenza Putignani, Aurelia Rughetti, Paolo Marchetti, Marianna Nuti, Andrea Botticelli, Chiara Napoletano
Journal of Personalized Medicine, 2020 - Tissue immune profile: A tool to predict response to neoadjuvant therapy in triple negative breast cancer
Bruna Cerbelli, Simone Scagnoli, Silvia Mezi, Alessandro De Luca, Simona Pisegna, Maria Ida Amabile, Michela Roberto, Lucio Fortunato, Leopoldo Costarelli, Angelina Pernazza, Lidia Strigari, Carlo Della Rocca, Paolo Marchetti, Giulia d’Amati, Andrea Botticelli
Cancers, 2020 - Exploratory pilot study of circulating biomarkers in metastatic renal cell carcinoma
Ilaria Grazia Zizzari, Chiara Napoletano, Alessandra Di Filippo, Andrea Botticelli, Alain Gelibter, Fabio Calabrò, Ernesto Rossi, Giovanni Schinzari, Federica Urbano, Giulia Pomati, Simone Scagnoli, Aurelia Rughetti, Salvatore Caponnetto, Paolo Marchetti, Marianna Nuti
Cancers, 2020 - Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1
Andrea Botticelli, Silvia Mezi, Giulia Pomati, Bruna Cerbelli, Edoardo Cerbelli, Michela Roberto, Raffaele Giusti, Alessio Cortellini, Luana Lionetto, Simone Scagnoli, Ilaria Grazia Zizzari, Marianna Nuti, Maurizio Simmaco, Paolo Marchetti
Frontiers in Immunology, 2020 - Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study
Olga Nigro, Graziella Pinotti, Federica De Galitiis, Francesca Romana Di Pietro, Raffaele Giusti, Marco Filetti, Melissa Bersanelli, Alessandro Lazzarin, Paola Bordi, Annamaria Catino, Pamela Pizzutilo, Domenico Galetta, Paolo Marchetti, Andrea Botticelli, Simone Scagnoli, Marco Russano, Daniele Santini, Mariangela Torniai, Rossana Berardi, Biagio Ricciuti, Andrea De Giglio, Rita Chiari, Alessandro Russo, Vincenzo Adamo, Marianna Tudini, Rosa Rita Silva, Elena Bolzacchini, Monica Giordano, Pietro Di Marino, Michele De Tursi, Erika Rijavec, Michele Ghidini, Ilaria Vallini, Luigia Stefania Stucci, Marco Tucci, Laura Pala, Fabio Conforti, Paola Queirolo, Enrica Tanda, Francesco Spagnolo, Federica Cecchi, Sergio Bracarda, Serena Macrini, Matteo Santoni, Nicola Battelli, Maria Concetta Fargnoli, Giampiero Porzio, Alessandro Tuzi, Matteo Basilio Suter, Corrado Ficorella, Alessio Cortellini
European Journal of Cancer, 2020 - The agnostic role of site of metastasis in predicting outcomes in cancer patients treated with immunotherapy
Andrea Botticelli, Alessio Cirillo, Simone Scagnoli, Bruna Cerbelli, Lidia Strigari, Alessio Cortellini, Laura Pizzuti, Patrizia Vici, Federica De Galitiis, Francesca Romana Di Pietro, Edoardo Cerbelli, Michele Ghidini, Giulia D’Amati, Carlo Della Rocca, Silvia Mezi, Alain Gelibter, Raffaele Giusti, Enrico Cortesi, Paolo Antonio Ascierto, Marianna Nuti, Paolo Marchetti
Vaccines, 2020 - Adjuvant chemotherapy in resected colon cancer: When, how and how long?
Alain J. Gelibter, Salvatore Caponnetto, Federica Urbano, Alessandra Emiliani, Simone Scagnoli, Grazia Sirgiovanni, Valerio M. Napoli, Enrico Cortesi
Surgical Oncology, 2019 - Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience
Laura Pizzuti, Antonio Giordano, Andrea Michelotti, Marco Mazzotta, Clara Natoli, Teresa Gamucci, Claudia De Angelis, Elisabetta Landucci, Lucrezia Diodati, Laura Iezzi, Lucia Mentuccia, Agnese Fabbri, Maddalena Barba, Giuseppe Sanguineti, Paolo Marchetti, Silverio Tomao, Luciano Mariani, Ida Paris, Vito Lorusso, Simona Vallarelli, Alessandra Cassano, Francesca Aroldi, Armando Orlandi, Luca Moscetti, Domenico Sergi, Maria Giuseppina Sarobba, Giuseppe Tonini, Daniele Santini, Valentina Sini, Enzo Veltri, Angela Vaccaro, Laura Ferrari, Michele De Tursi, Nicola Tinari, Antonino Grassadonia, Filippo Greco, Andrea Botticelli, Nicla La Verde, Claudio Zamagni, Daniela Rubino, Enrico Cortesi, Valentina Magri, Giulia Pomati, Simone Scagnoli, Elisabetta Capomolla, Ramy Kayal, Angelo Fedele Scinto, Domenico Corsi, Marina Cazzaniga, Lucio Laudadio, Samantha Forciniti, Maria Mancini, Luisa Carbognin, Patrizia Seminara, Sandro Barni, Riccardo Samaritani, Mario Roselli, Ilaria Portarena, Antonio Russo, Corrado Ficorella, Katia Cannita, Silvia Carpano, Mirco Pistelli, Rossana Berardi, Ruggero De Maria, Isabella Sperduti, Gennaro Ciliberto, Patrizia Vici
Journal of Cellular Physiology, 2019 - Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study
Maria Di Bartolomeo, Monica Niger, Giuseppe Tirino, Angelica Petrillo, Rosa Berenato, Maria Maddalena Laterza, Filippo Pietrantonio, Federica Morano, Maria Antista, Sara Lonardi, Lorenzo Fornaro, Stefano Tamberi, Elisa Giommoni, Alberto Zaniboni, Lorenza Rimassa, Gianluca Tomasello, Teodoro Sava, Massimiliano Spada, Tiziana Latiano, Alessandro Bittoni, Alessandro Bertolini, Ilaria Proserpio, Katia Bruna Bencardino, Francesco Graziano, Giordano Beretta, Salvatore Galdy, Jole Ventriglia, Simone Scagnoli, Andrea Spallanzani, Raffaella Longarini, Ferdinando De Vita
Targeted Oncology, 2018 - Burned-out testicular cancer: Really a different history
Claudia Mosillo, Simone Scagnoli, Giulia Pomati, Salvatore Caponnetto, Maria Laura Mancini, Mario Bezzi, Enrico Cortesi, Alain Gelibter
Case Reports in Oncology, 2017
